# Bristol Myers Squibb

для Breyanzi (лизокабтаген маралеуцел, CD19) обновление мониторинга и активности одобрено в Канаде в июне 2026 года, а BMS совместно разрабатывает Abecma (идекабтаген виклеуцел, BCMA) с 2seventy bio при множественной миеломе.

Source: https://bioecon.ru/companies/bristol-myers-squibb/
Updated: 2026-07-11

- Страна: United States
- Тикер: BMY

## Проверяемые факты

| Факт | Значение | Источник |
| --- | --- | --- |
| Выручка | $48.2 млрд в 2025 | https://www.bms.com/investors/financial-reporting/key-facts.html, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm |
| Численность | От примерно 5,000 сотрудников (операции клеточной терапии) до 34,100 (по компании в целом) | https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/ |
| Производственная площадка | Девенс, Массачусетс (клеточная терапия) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Производственная площадка | Ботелл, Вашингтон; Саммит, Нью-Джерси; Уоррен, Нью-Джерси (клеточная терапия) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Производственная площадка | Лейден, Нидерланды (клеточная терапия, в разработке или завершено) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Регуляторное одобрение | Обновление по мониторингу и активности Breyanzi одобрено в Канаде в июне 2026; обновления инструкций по применению Breyanzi и Abecma в США в июне 2025 | https://investors.bms.com/iframes/press-releases/press-release-details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://www.bms.com/assets/bms/ca/documents/productmonograph/BREYANZI_EN_PM.pdf, https://www.bms.com/ca/en/media/press-release-listing/2026-06-17-press-release.html, https://www.hematologyadvisor.com/news/fda-removes-rems-reduces-monitoring-requirements-for-breyanzi-and-abecma/ |
| Мощность | Расширение за счёт новых площадок (Девенс, Лейден) и инновационных производственных решений [средняя достоверность] | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |

Независимые источники: bms.com, contractpharma.com, fiercepharma.com, hematologyadvisor.com, investors.bms.com, news.bms.com, sec.gov

## Технологии

- [CAR-T клеточная терапия](https://bioecon.ru/technology/car-t-cell-therapy/)
- [Биофармацевтика и биомедицина](https://bioecon.ru/technology/biopharmaceuticals-biomedicines/)